Key points from article :
Vivodyne, founded by University of Pennsylvania bioengineers, secures $38 million seed financing led by Khosla Ventures.
The platform uses lab-grown human organs to test drugs before they enter clinical trials.
Vivodyne's technology can generate realistic, scalable, and reproducible human data in weeks.
The company has developed over 20 human organ models that mimic native human functions.
Vivodyne's platform can cultivate, dose, and image over 8,000 individual tissues simultaneously.
The company's technology has already attracted collaborations with a majority of the top 10 large pharmaceutical companies.